Matsumoto, Kimihiro <br/><br/>
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.  [electronic resource] 

 -  International journal of hematology  Jun 2015 
 - 554-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1865-3774 
<br/><br/><label>Standard No.: </label>10.1007/s12185-015-1767-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>B-Lymphocytes--drug effects<br/>Bendamustine Hydrochloride--adverse effects<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Leukopenia--chemically induced<br/>Lymphoma, B-Cell--drug therapy<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neutropenia--chemically induced<br/>Rituximab--administration & dosage<br/>Treatment Outcome<br/>Young Adult